How to judge animal models of Parkinson's disease in terms of neuroprotection.
Ideally, animal models of Parkinson's should reproduce the clinical manifestation of the disease, a loss of some but not all dopaminergic neurons, a loss of some non dopaminergic neurons and alpha-synuclein positive inclusions resembling Lewy bodies. There are at least three ways to develop animal models of PD. The first two are based on the etiology of the disease and consist in 1) reproducing in animals the mutations seen in inherited forms of PD; 2) intoxicating animals with putative environmental toxins causing PD. The last method currently used, which is not exclusive of the first two, is to try to reproduce the molecular or biochemical changes seen post-mortem in the brain of patients with PD. In this review we discuss the advantages and the drawbacks in term of neuroprotection of the currently used models.
Hirsch
E C
EC
INSERM U679, Hôpital de la Salpêtrière, Université Pierre et Marie Curie-Paris 6, Paris, France. hirsch@ccr.jussieu.fr
D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009498:Neurotoxins / Q000633:toxicity; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics; D010302:Parkinson Disease, Secondary / Q000139:chemically induced
D018696:Neuroprotective Agents; D009498:Neurotoxins